Tokyo Tech News

The story of thalidomide continues

Molecular basis of drug’s effects on limb and ear development revealed


Published: October 8, 2019

An international study co-authored by researchers at Tokyo Tech has unveiled a detailed view of how thalidomide, one of the most notorious drugs ever developed, causes abnormalities in limb and ear development. The findings may contribute to the re-emergence of safe, or non-teratogenic, thalidomide-derived drugs as a treatment for cancer and inflammatory diseases.

The newly proposed model of how thalidomide affects limb and ear development

Figure 1. The newly proposed model of how thalidomide affects limb and ear development

Thalidomide binds to cereblon (CRBN) and causes abnormal limb and ear development by inducing the breakdown of proteins called ∆Np63α and TAp63α through a process known as ubiquitination. This model suggests that the defects are triggered through downregulation of growth factors called Fgf8 and Atoh1.

Researchers in Japan and Italy have deepened understanding of the way in which thalidomide causes developmental abnormalities at the molecular level.

Thalidomide has a reputation as one of the most potent substances that can cause birth defects. Originally used in the late 1950s as a treatment for morning sickness, evidence in the early 1960s linked thalidomide to abnormalities including shortened limbs and defective organs, which led to its ban around the world.

Remarkably, based on subsequent findings that highlighted thalidomide's anti-inflammatory and other beneficial properties, the drug has become a major example of one that can be repurposed to treat conditions such as leprosy and multiple myeloma, a type of blood cancer.

"The thalidomide tragedy is not an open-and-shut case in medical history, but is ongoing," explains biochemist Yuki Yamaguchi of Tokyo Institute of Technology (Tokyo Tech), "as new thalidomide babies have been born after its re-approval in around 2000."

"But we now know that thalidomide and its derivative drugs are highly effective and are associated with few side-effects, except for the teratogenic effects on the fetus, unlike many other conventional anti-cancer agents," he points out. "Therefore, teratogenicity remains a big hurdle for wider application of these promising drugs."

To investigate the mechanisms behind thalidomide activity in more detail, Yamaguchi collaborated with Hiroshi Handa of Tokyo Medical University, Luisa Guerrini of Università degli Studi di Milano, Italy, and others to conduct developmental studies using zebrafish as a model organism. This collaboration set out to explore Guerrini's hunch that the p63 family of proteins might be critically involved. In 2010, a team led by Handa and Yamaguchi achieved a breakthrough by identifying cereblon as a key protein through which thalidomide initiates its adverse or teratogenic effects. (See Molecular Basis of Brain Dysfunction and Embryo Malformation Associated with Thalidomide.)

Now, the latest study published in Nature Chemical Biology shows that after binding to cereblon, thalidomide causes damage to fins (corresponding to limbs) and to otic vesicles (corresponding to ears) by inducing the breakdown of two types of p63 proteins. Specifically, the study suggests that the breakdown of ∆Np63α results in limb defects, while that of TAp63α leads to ear defects, as shown in Figure 1.

Understanding how cereblon works to mediate the effects of thalidomide could transform the way drugs are developed — moving away from serendipitous discovery and towards rational molecular design. "The change would be like a shift from looking for a needle in a haystack to carving a needle out of bone," Yamaguchi notes.

"It's likely that we will see the development of new thalidomide-based drugs without teratogenic effects in the near future," he says.


Authors :
Tomoko Asatsuma-Okumura1,5, Hideki Ando1,5, Marco De Simone2, Junichi Yamamoto1,5, Tomomi Sato1,5, Nobuyuki Shimizu1,5, Kazuhide Asakawa1,5, Yuki Yamaguchi3, Takumi Ito1,4,5, Luisa Guerrini2* and Hiroshi Handa1,5
Title of original paper :
p63 is a cereblon substrate involved in thalidomide teratogenicity
Journal :
Nature Chemical Biology (2019)
Affiliations :

1Department of Nanoparticle Translational Research, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

2Department of Biosciences, Università degli Studi di Milano, Milan, Italy.

3School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan.

4PRESTO, JST, 4-1-8 Honcho, Kawaguchi, Japan.

5National Center for Geriatrics and Gerontology (NCGG)

6Present Address: Department of Chemical Biology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

School of Life Science and Technology

School of Life Science and Technology
—Unravel the Complex and Diverse Phenomena of Life—

Information on School of Life Science and Technology inaugurated in April 2016

School of Life Science and Technology

Schools, Departments, and Institute for Liberal Artsouter

Further Information

Professor Yuki Yamaguchi

School of Life Science and Technology, Tokyo Institute of Technology

Tel +81-45-924-5798


Public Relations Section, Tokyo Institute of Technology

Tel +81-3-5734-2975